Literature DB >> 15184633

Low levels of the vascular endothelial growth factor in CSF from early ALS patients.

D Devos1, C Moreau, P Lassalle, T Perez, J De Seze, V Brunaud-Danel, A Destée, A B Tonnel, N Just.   

Abstract

Deletion of the hypoxia-response element in the vascular endothelial growth factor (VEGF) promoter causes motor neuron degeneration in a mouse model. "At-risk" haplotypes with low circulating VEGF levels have been demonstrated in humans. Here the authors report low VEGF levels in the CSF of ALS patients during their first year of the disease, independently of VEGF promoter polymorphism. This finding early in ALS patients suggests a possible role for VEGF gene regulation in the pathogenesis of ALS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184633     DOI: 10.1212/01.wnl.0000129913.44351.a3

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

1.  Evolution of the VEGF-regulated vascular network from a neural guidance system.

Authors:  Sreenivasan Ponnambalam; Mario Alberghina
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

Review 2.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

3.  TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells.

Authors:  Claudia Colombrita; Elisa Onesto; Francesca Megiorni; Antonio Pizzuti; Francisco E Baralle; Emanuele Buratti; Vincenzo Silani; Antonia Ratti
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

4.  Amyotrophic lateral sclerosis after embolization of cerebral arterioveneous malformations.

Authors:  Anton Valavanis; Urs Schwarz; Christian R Baumann; Michael Weller; Michael Linnebank
Journal:  J Neurol       Date:  2014-02-08       Impact factor: 4.849

Review 5.  Hypoxia inducible factor-1 as a target for neurodegenerative diseases.

Authors:  Z Zhang; J Yan; Y Chang; S ShiDu Yan; H Shi
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 6.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

7.  Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS.

Authors:  C Moreau; D Devos; V Brunaud-Danel; L Defebvre; T Perez; A Destée; A B Tonnel; Ph Lassalle; N Just
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

8.  Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.

Authors:  G Yacila; Y Sari
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

9.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

Review 10.  Biomarkers in amyotrophic lateral sclerosis: facts and future horizons.

Authors:  Pierre-François Pradat; Michel Dib
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.